CompletedPhase 2NCT01511978
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Studying Lambert-Eaton myasthenic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jacobus Pharmaceutical
- Principal Investigator
- Kathy L Aleš, MDJacobus Pharmaceutical
- Intervention
- Continuous 3,4-DAP(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2015
Study locations (7)
- University of California at Davis, Sacramento, California, United States
- Indiana University, Indianapolis, Indiana, United States
- Duke University, Durham, North Carolina, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Baylor College of Medicine, Houston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01511978 on ClinicalTrials.gov